Enzyme News and Research

RSS

Exploiting biology's own chemical toolbox...

Exploiting biology's own chemical toolbox, researchers have developed a new technique that will allow them to modify specific sequences within a DNA molecule. The approach will not only help reveal the impact of biochemical alterations to DNA, but could have far-reaching implications for DNA-based medical diagnosis and nanobiotechnology.

28 Nov 2005

Cranberry flavoured toothpaste may help stop decay

According to researchers cranberries, well-known for their ability to help thwart urinary tract infections, may also help prevent tooth decay and cavities.

28 Nov 2005

Spear Therapeutics raise $8.5 Million to fund cancer drug development

Cancer Research Technology (CRT), Bloomsbury Bioseed Fund (BBSF), De Montfort University (DMU) and the Gray Cancer Institute announce today that U.S. venture capital firm Advent International has invested $8.5 million in Spear Therapeutics Ltd.

28 Nov 2005

Study finds AKT blocks cancer cell motility

PIn investigating the molecular mechanisms of cancer cell motility - the unique property that enables cancer to spread from its primary origin to other parts of the body - researchers have uncovered a surprising role for the AKT/PKB (protein kinase B) enzyme

26 Nov 2005

Potential drug target for malaria

Researchers have identified an enzyme crucial to the malaria parasite's invasion of red blood cells, according to a study in the open-access journal, PLoS Pathogens.

26 Nov 2005

Cranberry juice protects teeth against cavities

Families gathered around the Thanksgiving dinner table might consider giving thanks for the bacteria-busting ability of cranberry juice, say dental researchers who have discovered that the beverage holds important clues for preventing cavities.

26 Nov 2005

Carbonic anhydrase and CO2 sensing during Cryptococcus neoformans growth, differentiation, and virulence

By using pathogenic fungi as model systems for understanding fungal diseases, two groups of researchers are reporting new work that offers insight into how carbon dioxide (CO2) governs the morphogenic changes that allow pathogenic fungi to survive in different environments and invade the human body

21 Nov 2005

Persistent amyloidosis following suppression of Ab production in a transgenic model of Alzheimer disease

Alzheimer Disease (AD) is characterized by hallmark lesions called amyloid plaques in the brain.

20 Nov 2005

Why some people do not respond as well as others to statin therapy

A newly discovered genetic variation, in combination with a second variation, reduces the ability of statin drugs to lower "bad" LDL cholesterol, researchers report at the American Heart Association's Scientific Sessions 2005.

20 Nov 2005

New gene linked to schizophrenia and depression

A Scots-led medical research team has identified a new gene linked to major mental illness that links back to a previously discovered gene known to increase the risk of schizophrenia and depression.

20 Nov 2005

Genetically modified allow scientists to examine the potential usefulness of new therapies for Alzheimer's disease

Researchers with the University of Florida and the California Institute of Technology have developed a new strain of genetically modified mice that allow scientists to examine the potential usefulness of new therapies for Alzheimer's disease.

20 Nov 2005

Lowering calorie intake may help Parkinson's disease

A new Oregon Health & Science University and Portland Veterans Affairs Medical Center study suggests that early-stage Parkinson's disease patients who lower their calorie intake may boost levels of an essential brain chemical lost from the neurodegenerative disorder.

20 Nov 2005

Plant extract forskolin may lead to leukemia treatment

Scientists here have identified a new pathway in the progression of chronic myelogenous leukemia (CML). They also discovered that an extract from the root of a common ornamental plant can suppress the process.

20 Nov 2005

Six gene variants predict heart muscle damage after cardiac surgery

Duke University Medical Center researchers have found that patients with six specific variants of genes involved in the body's immune response are significantly more likely to suffer damage of heart tissue after cardiac surgery.

16 Nov 2005

Mayo Clinic provides new strategy for designing better treatments for juvenile dermatomyositis

Mayo Clinic researchers, working with colleagues at the University of Minnesota and University of Pittsburgh, are the first to describe a new role for a specialized cell of the immune system in children suffering from a rare muscle-damaging disease known as juvenile dermatomyositis (JDM).

14 Nov 2005

Link between diet and epileptic seizures studied

Although the high-fat, calorie-restricted ketogenic diet (KD) has long been used to prevent childhood epileptic seizures that are unresponsive to drugs, physicians have not really understood exactly why the diet works.

13 Nov 2005

Lifelong exercise decreases cellular aging in the brain

In the first study to show that lifelong exercise decreases cellular aging in the brain, scientists from the McKnight Brain Institute of the University of Florida say that moderately active rats have healthier DNA and more robust brain cells than their less active counterparts. The research was presented at the Society for Neuroscience's 35th annual meeting in Washington, D.C.

13 Nov 2005

Non-steroidal anti-inflammatory drugs may prevent the development of oesophageal adenocarcinoma in patients with Barrett's oesophagus

Barrett’s oesophagus is a metaplastic disorder that develops in about 10% of people with chronic gastro-oesophageal reflux disease. Every year about 0.5%-1% of patients with Barrett’s oesophagus develop oesophageal adenocarcinoma.

10 Nov 2005

Aspirin and ibuprofen may significantly reduce the risk of esophageal cancer among people with Barrett's esophagus

Aspirin and other nonsteroidal anti- inflammatory drugs, such as ibuprofen, may significantly reduce the risk of esophageal cancer among people with Barrett's esophagus, a precancerous condition associated with chronic heartburn that affects an estimated 1 million to 2 million Americans.

8 Nov 2005

Introgen's INGN 241 combined with Celebrex kills breast cancer cells

Introgen Therapeutics, Inc. today reported the publication of preclinical data demonstrating that INGN 241 works synergistically with celecoxib (Celebrex) marketed by Pfizer to inhibit the growth and increase apoptosis (cell death) of breast cancer cells.

8 Nov 2005